

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	
Background	7
Objective and Scope	7
Selection of Topics for Monographs.....	8
Data for Monographs	9
The Working Group.....	9
Working Procedures.....	9
Exposure Data.....	10
Studies of Cancer in Humans.....	12
Studies of Cancer in Experimental Animals.....	15
Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms.....	18
Summary of Data Reported	19
Evaluation	21
References.....	25
GENERAL REMARKS	29
THE MONOGRAPHS	
Benzodiazepines and related compounds and phenytoin	35
Diazepam	37
Doxefazepam	97
Estazolam.....	105
Oxazepam	115
Prazepam.....	143
Ripazepam.....	157
Temazepam.....	161
Phenytoin	175
Anti-oestrogenic compounds	239
Droloxifene	241
Tamoxifen	253
Toremifene.....	367

Hypolipidaemic drugs	389
Clofibrate	391
Gemfibrozil	427
SUMMARY OF FINAL EVALUATIONS	445
GLOSSARY	447
APPENDIX 1. SUMMARY TABLES OF GENETIC AND RELATED EFFECTS	451
APPENDIX 2. ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS	467
SUPPLEMENTARY CORRIGENDA TO VOLUMES 1–65	485
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES	487

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.